AstraZeneca (AZN)
Bid | 67.7 |
Market Cap | 420.94B |
Revenue (ttm) | 54.07B |
Net Income (ttm) | 7.04B |
EPS (ttm) | 2.25 |
PE Ratio (ttm) | 30.17 |
Forward PE | 14.74 |
Analyst | Buy |
Ask | 68.99 |
Volume | 4,137,161 |
Avg. Volume (20D) | 6,156,913 |
Open | 68.06 |
Previous Close | 68.01 |
Day's Range | 67.32 - 68.40 |
52-Week Range | 61.24 - 87.68 |
Beta | 0.25 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardi...
Analyst Forecast
According to 7 analyst ratings, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $90, which is an increase of 32.58% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

6 days ago · proactiveinvestors.co.uk
AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacleAstraZeneca PLC (LSE:AZN) is due to report first-quarter earnings on April 29, and UBS is bracing for a modest miss against market expectations, though the bank maintains a broadly supportive stance o...

6 days ago · proactiveinvestors.co.uk
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change thatUBS has warned that drugmakers such as AstraZeneca and GSK could be among the most exposed in Europe's pharmaceuticals sector should President Trump follow through on threats to impose new levies on t...